Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in melanoma
- Trial result
Melanoma
Melphalan ILP (regional alkylator): CD8+ phenotype predicts CR in in-transit melanoma
Melphalan-based isolated limb perfusion (ILP) delivers high-dose regional alkylating chemotherapy; this single-center retrospective study (Sweden) tested whether baseline peripheral-blood immunophenotype predicts…
NCT03685890 - Trial result Spotlight
Melanoma
FMT + Anti-PD-1 Delivers 65% ORR and mPFS 29.6 mo in Frontline Melanoma
The MIMic phase I trial (multicenter; NCT03772899) gave a single oral fecal-microbiota transplant (healthy-donor stool) followed by standard anti-PD-1 as first-line therapy for advanced melanoma (n=20). ORR was 65%…
NCT03772899 - Trial result
Melanoma
Neoadjuvant Nivo + Relatlimab (PD-1 / LAG-3) Yields 80% 4-Year EFS in Resectable Stage III-IV Melanoma
Relatlimab (anti-LAG-3) plus nivolumab (anti-PD-1) was given peri-operatively in the single-arm Phase II NCT02519322 study. Thirty patients with resectable stage III/IV melanoma received two neoadjuvant doses,…
NCT02519322 - Trial result
Melanoma
Oncolytic HSV‑1 RP1 plus PD‑1 blockade yields 33% ORR in PD‑1‑refractory melanoma
Vusolimogene oderparepvec (RP1) is an intratumoral HSV‑1 oncolytic virus engineered to secrete GM‑CSF and drive syncytia formation; in the single‑arm Phase II IGNYTE cohort (NCT03767348) it was paired with nivolumab…
NCT03767348 - New trial Spotlight
Melanoma
Phase 2 trial: V940 mRNA cancer vaccine & Pembrolizumab PD-1 inhibitor in advanced melanoma
This Phase 2 study evaluates whether a patient-specific TAA mRNA vaccine (V940) given by IM injection alongside IV pembrolizumab (a PD-1 inhibitor) can prolong progression-free survival compared to placebo plus…
NCT06961006 Exploratory - New trial
Melanoma
Phase 2 anti-PD-1 checkpoint inhibitor trial comparing selective vs therapeutic lymph node dissection in melanoma
This study aims to determine non-inferiority in 2-year recurrence-free survival among Stage III melanoma patients receiving neoadjuvant anti-PD-1 immunotherapy (a checkpoint inhibitor that reactivates immune…
NCT07049276 Exploratory - Trial result Spotlight
Melanoma
Pembrolizumab + ATRA (MDSC-Targeting) Posts 55% 5-Year OS in Metastatic Melanoma
All-trans retinoic acid (ATRA), a differentiating agent that depletes immunosuppressive myeloid-derived suppressor cells, was pulsed at 150 mg/m² orally on days −1/0/+1 of the first four pembrolizumab 200 mg Q3W…
NCT03200847 - Trial result
Melanoma
Nivolumab + Relatlimab Posts 52% 4-Year OS in First-Line Advanced Melanoma
Nivolumab (PD-1) plus relatlimab (LAG-3) fixed-dose (Opdualag) outperformed nivolumab alone in the phase 2/3 RELATIVITY-047 trial (n = 714 treatment-naïve stage III/IV melanoma): 4-year PFS 30.6% vs 23.6%, OS 52.0%…
- Trial result Spotlight
Melanoma
ROR2-targeted ADC ozuriftamab achieves 80% response and 5-year CR in refractory melanoma
Ozuriftamab vedotin is a conditionally active anti-ROR2 antibody–drug conjugate that releases MMAE within the acidic tumor microenvironment. ROR2 is expected to be important to signaling in melanoma and is expressed…
NCT03504488 - Trial result
Melanoma
Oncolytic HSV RP1 + PD-1 blockade nets 33% ORR and mDOR of 33.7 months, systemic lesion shrinkage in refractory melanoma
Vusolimogene oderparepvec (RP1) is a GM-CSF/fusogenic glycoprotein-armed oncolytic HSV-1 that was injected into tumors alongside nivolumab in the single-arm Phase II IGNYTE registrational cohort (NCT03767348). Among…
NCT03767348 - Trial result
Melanoma
Nivolumab + Relatlimab Shows 22% Intracranial Response in PD-1–Refractory Melanoma Brain Mets
In the Phase I/IIa RELATIVITY-020 trial (NCT01968109), nivolumab (anti-PD-1) plus relatlimab (anti-LAG-3) was evaluated in 27 heavily pre-treated patients with measurable melanoma brain metastases. All patients…
NCT01968109 - Trial result
Melanoma
High-Dose BCNU Chemoembolization Yields 93% Disease Control in First-Line Hepatic-Dominant Uveal Melanoma
In the single-arm phase 2 (NCT04728633) trial, 28 treatment-naïve patients with <50% liver involvement and minimal extrahepatic spread received trans-arterial chemo-embolization (TACE) with 300 mg carmustine (BCNU)…
NCT04728633 - Trial result
Melanoma
Melphalan/Hepatic Delivery System Achieves 46% ORR in First-line Liver-Dominant Uveal Melanoma
Melphalan/HDS delivers high-dose alkylator directly into the hepatic artery with extracorporeal chemofiltration, aiming to control the liver—the first and often only metastatic site in uveal melanoma. In the…
NCT05022901 - Trial result
Melanoma
Tocilizumab + Ipilimumab/Nivolumab Links Lower Early Grade ≥3 irAEs (43% vs ~60%) to Th17 Dampening in Front-Line Melanoma
In the phase I/II (NCT04940299) study, 35 treatment-naïve advanced melanoma patients received ipilimumab 3 mg/kg + nivolumab 1 mg/kg every 3 weeks plus weekly (162 mg, n = 16) or bi-weekly (n = 19) subcutaneous…
NCT04940299 - Trial result
Melanoma
Nivolumab + Relatlimab Shows 22% Intracranial Response in PD-1–Refractory Melanoma Brain Mets and likely doubles survival
Nivolumab plus relatlimab, a PD-1/LAG-3 checkpoint pair, was evaluated in the phase I/IIa RELATIVITY-020 post-hoc brain-metastasis analysis (NCT01968109). Twenty-seven heavily pre-treated patients (100% prior…
NCT01968109 - Trial result
Melanoma
Ozuriftamab Vedotin Shrinks Tumors in 4 out of 5 Refractory Melanoma Patients via ROR2-Targeted α-MMAE Delivery
Ozuriftamab vedotin is a conditionally active antibody-drug conjugate that binds the non-canonical WNT receptor ROR2 and releases MMAE preferentially in the acidic tumor milieu. In the first-in-human phase 1 study…
NCT03504488 - Trial result
Melanoma
RP1 (VSV-GM-CSF) + Nivolumab Shrinks 97% of Injected and 97% of Bystander Lesions in PD-1–Refractory Melanoma
RP1, an oncolytic vaccine armed with GM-CSF and fusogenic GALV-GP-RCT, was injected Q2W into superficial and/or image-guided visceral tumors alongside nivolumab IV (240 mg Q2W) in 140 anti-PD-1–failed melanoma…
NCT03767348 - New trial
Melanoma
Phase 1 Study of GME751, PD-L1/PD-L2 Inhibitor in Melanoma Adjuvant Setting
This randomized, double-blind study compares the pharmacokinetics, efficacy, safety, and immunogenicity of GME751 versus US-/EU-licensed pembrolizumab administered intravenously as adjuvant therapy in patients with…
NCT06153238 - Trial result
Melanoma
Nivolumab + Ipilimumab First Doubles 5-Year OS vs Dabrafenib/Trametinib in BRAFV600-Mutant Melanoma
In the Phase III DREAMseq trial (NCT02224781), 267 untreated patients with BRAF V600-mutant metastatic melanoma were randomized to receive either nivolumab (a PD-1–directed monoclonal antibody) plus ipilimumab (a…
NCT02224781 - Trial result
Melanoma
One-Time TIL Therapy Lifileucel Delivers 31% ORR with 3-Year Median Response and 20% 5-Year Survival in Heavily Pretreated Melanoma
Lifileucel is an autologous tumor-infiltrating lymphocyte (TIL) product administered following non-myeloablative lymphodepletion and high-dose interleukin-2 (IL-2). In the Phase 2 C-144-01 trial (*n* = 153; median of…
- New trial
Melanoma
Phase I/II Clinical Trial of CD40L-augmented Tumor Infiltrating Lymphocytes (TIL) for Advanced Melanoma
This trial is evaluating a single dose of CD40L-augmented TIL therapy in advanced melanoma patients—including those with rare subtypes—after failure of standard treatment, with lymphodepletion and a short course of…
NCT06961357 - New trial
Melanoma
Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
This phase 2, single‐arm trial is evaluating the combination of pembrolizumab and metronomic cyclophosphamide in patients with refractory, unresectable non-ocular stage III/IV melanoma. Sponsored by UC Irvine, the…
NCT06771544 - New trial
Melanoma
Phase 2 Trial: Adjuvant Quisinostat in High-Risk Uveal Melanoma
University of Miami is evaluating whether quisinostat, an HDAC inhibitor, can prevent metastatic spread in high-risk uveal melanoma when used as adjuvant therapy. Participants receive up to 17 cycles over 51 weeks…
NCT06932757 - New trial
Melanoma
Cytophone Liquid Biopsy Aims for Early Detection of Metastatic Melanoma
Cytoastra’s trial in Madison is evaluating the Cytophone—a noninvasive photoacoustic flow cytometry tool that detects and counts circulating melanoma cells—to provide an early risk assessment of metastasis. This…
NCT06488365 - New trial
Melanoma
Phase 1/2 Trial of IOV-3001 Plus Lifileucel in Advanced Melanoma
Iovance Biotherapeutics in Nashville is launching an open-label study evaluating a modified interleukin-2 fusion protein (IOV-3001) in combination with lifileucel for previously treated unresectable or metastatic…
NCT06940739
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.